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It's Not You, It's Me:
Necessity of Including Cultural
Factors in Clinical Research
Shard6 C. Thomast
Introduction
An estimated 20-30% of all United States clinical trials are
outsourced to countries such as Poland, India, and Mexico.' For
both domestic and outsourced clinical trials, language barriers and
a lack of cultural understanding are a constant source of
problems.2 In 1993, the National Institutes of Health
Revitalization Act (NIHRA) was passed with a provision requiring
minorities and women to be included in clinical research.' Section
131 of the Act was passed in an attempt to prevent and correct the
frequent exclusion and improper treatment of minority
participants in clinical research.4 The Act applies to research
being conducted or supported by the National Institute of Health,'
and provides that minorities should be included as subjects, unless
an exception applies rendering the requirement inapplicable.' In
practice, researchers still have difficulty including diverse
t. J.D. expected 2012, University of Minnesota Law School. The author would
like to thank her friends, family, and the staff and editors of Law & Inequality: A
Journal of Theory and Practice. The author would also like to thank Professor
Michele Goodwin, Professor Ralph Hall, and Sara DeSanto for their assistance with
this article.
1. Karen Politis Virk, Global Clinical Trials: The Challenge of Language,
LANGUAGE CONNECTIONS, http://www.languageconnections.com/descargas/Global%
20Clinical%20trials%20challenge%20of%2Olanguage.pdf (last visited Sept. 22,
2011) (citing Press Release, Thomson CenterWatch, Thomson CenterWatch Tracks
Emerging Markets of Clinical Research (Apr. 19, 2007) (on file with author)).
2. Compare Virk, supra note 1 (discussing the challenges of international
clinical research), with Ctr. for Translational Sci. Activities, Community
Engagement and Minority Inclusion, MAYO CLINIC, http://ctsa.mayo.edu/resources/
community-engagement-minority-inclusion.html (last visited Sept. 22, 2011)
(providing guidance for clinical researchers within the United States).
3. National Institutes of Health Revitalization Act of 1993, 42 U.S.C. § 289a-2
(2006).
4. NAT'L INSTS. OF HEALTH OFFICE OF THE DIR., U.S. DEP'T OF HEALTH &
HUMAN SERVS., OUTREACH NOTEBOOK FOR THE INCLUSION, RECRUITMENT AND
RETENTION OF WOMEN AND MINORITY SUBJECTS IN CLINICAL RESEARCH 3-4 (2002)
[hereinafter OUTREACH NOTEBOOK].
5. Id.
6. 42 U.S.C. § 289a-2(b).
180 Law and Inequality [Vol. 30:179
populations in clinical research.7  This is especially true with
nonfluent English speakers because of the practical difficulties of
providing translations and interpretations, ensuring informed
consent, and complying with necessary follow-up.' Furthermore,
as occasionally happens with legislation, the vagueness of the Act's
language allows researchers to avoid including certain minorities.9
For example, the Act does not specifically address nonfluent
English speakers or those with unique cultural attributes,10
allowing these segments of the population to be excluded." Great
strides have been made since minorities first became part of
clinical research," but there is still a need for more comprehensive
legislation."
This Note examines the inclusion of diverse populations in
clinical research, specifically addressing the difficulty of
considering participants' cultural differences." Part I of the Note
7. THE ENDOCRINE Soc'Y, INCREASING MINORITY PARTICIPATION IN CLINICAL
RESEARCH 1 (2007).
8. E-mail from Sara DeSanto, Assoc. Gen. Counsel, Allina Hosps. & Clinics, to
author (Sept. 13, 2010, 12:46 CST) (on file with author); see also Yael Schenker et
al., The Impact of Language Barriers on Documentation of Informed Consent at a
Hospital with On-Site Interpreter Services, 22 J. GEN. INTERNAL MED. 294, 294
(2007) (discussing the impact of language barriers on the process of informed
consent in hospitals).
9. See 42 U.S.C. § 289a-2 (providing that women and "members of minority
groups" should be included unless certain exceptions apply, including if researchers
feel inclusion "is inappropriate").
10. Id.
Various subtle cultural differences can affect the way that clinical research
is conducted. For example, many cultures do not believe in fully disclosing
a patient's diagnosis; therefore, the potential risks of a clinical study may
also be culturally filtered. This can negatively affect the process of
informed consent. Another cultural difference which can interfere with
patient informed consent involves the patient/physician relationship.
More specifically, in many cultures patients are less likely to question a
physician's recommendations.
Virk, supra note 1.
11. See 42 U.S.C. § 289a-2; Ctr. for Translational Sci. Activities, supra note 2
(offering advisors to help with inclusion of different cultural aspects in clinical
research).
12. See, e.g., FRED D. GRAY, THE TUSKEGEE SYPHILIS STUDY: THE REAL STORY
AND BEYOND 48-73 (1998) (providing an example of minority involvement in an
early clinical study).
13. Paula Hartman Cohen, Comparative Effectiveness Research: Boon or
Burden for Minorities?, JUSTGARCIAHILL 1, 4-6 (2009), http://justgarciahill.org/
(search "Paula Hartman Cohen").
14. See Ctr. for Translational Sci. Activities, supra note 2 ("[L]anguage, health
beliefs, religion and more can hinder participation in clinical research. Knowledge
of cultural backgrounds and issues of concern to different communities are
essential in understanding the needs of the groups before research can begin.").
Many researchers mistakenly consider translating research documents into the
participant's language to be enough. See Virk, supra note 1.
ITS NOT YOU, ITS ME
explores the history of clinical research and the exclusion and
manipulation of minorities in clinical research. Part II discusses
the background and requirement of informed consent. Part III
discusses laws and efforts to include minorities in clinical
research. The final section focuses on the difficulties and inequal-
ities faced by non-English speakers participating in clinical
research. The Note concludes with recommendations for
amending the laws to ensure that all populations have appropriate
access to clinical trials.
I. Background of Minorities in Clinical Research
A. Clinical Research
Clinical research has a variety of definitions, both broad and
narrow." These definitions impact the amount of research that is
considered to be clinical research as well as what rules should be
followed.16 Clinical research is used for multiple purposes, such as
testing new treatments for diseases and ailments, testing a body's
interaction with new medications, and learning more about
diseases." It is a tool that was used by the ancient Egyptians"
and Chinese" and has evolved over time. 0
15. Compare John I. Gallin, A Historical Perspective on Clinical Research, in
PRINCIPLES AND PRACTICE OF CLINICAL RESEARCH 1, 1 (John I. Gallin & Frederick
P. Ognibene eds., 2d ed. 2007) (defining clinical research broadly using the
definition of the Association of American Medical Colleges Task Force on Clinical
Research: "a component of medical and health research intended to produce
knowledge essential for understanding human disease, preventing and treating
illness, and promoting health"), with What Is Clinical Research?, NAT'L INSTS.
HEALTH: EUNICE KENNEDY SHRIVER NAT'L INST. CHILD HEALTH & HUMAN DEV.,
http://www.nichd.nih.gov/health/clinicalresearch/ (last updated July 23, 2009)
(offering a more narrow definition of clinical research: "research that either
directly involves a particular person or group of people or uses materials from
humans, such as their behavior or samples of their tissue, that can be linked to a
particular living person").
16. See What Is Clinical Research?, supra note 15.
17. See Gallin, supra note 15 (explaining that studies involve "interaction with
patients, diagnostic clinical materials or data, or populations, . . . disease
mechanisms; translational research; clinical knowledge; detection; diagnosis and
natural history of disease; therapeutic interventions including clinical trials;
prevention and health promotion; behavioral research; health services research;
epidemiology; and community-based and managed care-based research").
18. Id. Imhotep, an Egyptian living around 3000 BC "was a known scribe,
priest, architect, astronomer, and magician (medicine and magic were used
together), and he performed surgery, practiced some dentistry, extracted medicine
from plants, and knew the position and function of the vital organs." Id. (citations
omitted).
19. Id. "[Iun 2327 BC Shen Nung, the putative father of Chinese medicine,
experimented with poisons and classified medical plants, and I. Yin . . , a famous
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Depending on what type of trial is underway, the process for
clinical research varies." Generally, the process involves trying
new therapies or medications, "evaluating the outcomes, and
publishing the results."2 2 Before clinical research can begin, it
must receive approval from the Food and Drug Administration.
Once approved, the four phases24 of clinical trial research begin.25
In addition to contributing to medical knowledge, clinical
research creates an opportunity for "free or reduced-cost access to
experimental therapies . . . for which insurance reimbursement
[would be] unlikely."2 6 Furthermore, it can be an alternative
means for those without health insurance to gain access to the
health care system.27 Others have even concluded that there is an
"inclusion benefit" achieved through participation in clinical
trials.28 Medicare beneficiaries currently receive coverage for the
cost of routine patient care during clinical research participation,29
but some have expressed concern about the American Recovery
prime minister of the Shang dynasty, described the extraction of medicines from
boiling plants." Id. (citations omitted).
20. Id. at 1-12.
21. Nat'l Insts. of Health, Understanding Clinical Trials, CLINICALTRIALS.GOV,
http://clinicaltrials.gov/ct2/info/understand#Q04 (last updated Sept. 20, 2007)
[hereinafter Understanding Clinical Trials].
22. John D. Lantos, The "Inclusion Benefit" in Clinical Trials, 134 J.
PEDIATRICS 130, 130 (1999).
23. Ron Chea, Clinical Research Trials Process, SuITE101 (Mar. 28, 2010),
http://www.suitel0l.com/content/clinical-research-trials-process-a21 9l 44 . Note
that "[ulsually, after 30 days, when the sponsors have not heard anything from the
FDA, they can start the study without checking with the FDA." Id.
24. Id. Phase I of drug trials involves "determin[ing] the acceptable drug
dosage, its route of administration, and its side effects. They also look at how the
investigational drug is metabolized in humans' body [sic] and how the body acts on
the new drug." Id. During Phase II, the research is centered on collecting evidence
that supports the claims of the new medication's efficacy. Id. Phase III involves
comparing the "new drug with the current drug that exists in the market. If the
investigational drug is more efficacious than the current drug, the sponsors file a
New Drug Application (NDA) with the FDA so that the sponsors could market the
new drug to the public." Id. Finally, in Phase IV, researchers complete a "post-
market study" with people who have been using the drug while it has been on the
market and consider other possible uses. Id.
25. Id.; see also NESBIT, CLINICAL RESEARCH: WHAT IT IS AND HOW IT WORKS
4-8 (Chambers Moore ed., 2004).
26. Barbara A. Noah, The Participation of Underrepresented Minorities in
Clinical Research, 29 AM. J.L. & MED. 221, 226 (2003).
27. See id. at 221-22.
28. Lantos, supra note 22. One example of an inclusion benefit occurred when
infants who were enrolled in a clinical trial, but received the placebo, had better
outcomes than infants who were not enrolled. Id.
29. Noah, supra note 26, at 227.
182 [Vol. 30:179
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and Reinvestment Act3" and the impact comparative effectiveness
research would have on the minority population."
Participants in clinical trials face an inherently uncertain
element of risk.32  They may experience "physical (death,
disability, infection), psychological (depression, anxiety), economic
(job loss), or social (for example, discrimination or stigma from
participating in a certain trial)" risks, all of which may range in
severity.3 Although adverse events are documented for future
use," the results can be long-term for the participant."
Ultimately, clinical researchers should always attempt to
minimize risks for participants.
B. Minorities Manipulated in or Excluded from Clinical
Research
Minorities have traditionally been excluded from clinical
research." "For reasons of scientific and practical convenience,
minority groups were commonly excluded from clinical trials until
the mid-1990s."3  If not excluded, only a small percentage of the
minority population was included in a particular study." On
numerous occasions, minorities were manipulated in clinical trials
30. American Recovery and Reinvestment Act of 2009, Pub. L. No. 111-5, 123
Stat. 115.
31. Cohen, supra note 13. Congressional Black Caucus members feared that
research would be used to develop "a 'one-size-fits-all' approach to treating
patients, ... negatively [impacting] anyone outside the majority." Id. They were
further concerned that the research would be used as a tool to "ration care," while
not considering "the impact of race, ethnicity, gender and geography on health and
health care." Id.
32. Nat'l Insts. of Health, Ethics in Clinical Research, NIH & CLINICAL RES.,
http://clinicalresearch.nih.gov/ethicsguides.html (last visited Sept. 22, 2011).
33. Id.
34. Lantos, supra note 22. The Systematic Evaluation of Research Risks
(SERR) is used as a mechanism to evaluate risks. Annette Rid et al., Evaluating
the Risks of Clinical Research, 304 JAMA 1472, 1472 (2010) ("[The SERR system]
evaluates the risks of research interventions by comparing these interventions with
the risks of comparator activities that have been deemed acceptable.").
35. Nat'l Insts. of Health, supra note 32.
36. Id.
37. Noah, supra note 26, at 225 ("[A] trend of under-inclusion of minorities in
research for reasons of scientific convenience . . . contribute[s] to lower
participation rates . . . ."). "Clinical trials for heart failure therapies also tend to
exclude non-white patients." Id. at 226. "Of thirteen studies that examined the
efficacy and/or safety of antihypertensive drugs ... only eight of them enrolled at
least one African-American subject, and investigators attempted to identify race-
based differential drug response in only one study." Id.
38. Noah, supra note 26, at 224.
39. Craig K. Svensson, Representation of American Blacks in Clinical Trials of
New Drugs, 261 JAMA 263, 264 (1989).
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by being given false or misleading information.40 Another study
found that "[e]ight studies [out of seventy-two] explicitly stated
they were on Caucasians or whites, and two excluded ethnic
minority groups using language and birthplace criteria.""
Learning from past injustices can help avoid similar treatment of
other underrepresented segments of the population.
1. Past Injustices
There is a long history of minorities being manipulated and
misled in clinical research; some instances are more well-known
than others.42 Many of the lesser-known early studies in the
United States involved slaves.' "During the nineteenth century,
'researchers' used African-American slaves as unwilling subjects
in a host of experiments dealing with medical phenomena such as
sunstroke, the perfection of surgical techniques and dissection
after death to improve their understanding of anatomy.""
Government agencies, such as the United States Publich Health
Service, supported studies that involved the manipulation of
minorities."
The Tuskegee study is one of the best-known examples of
abuse in clinical research.46 The study was held at the Tuskegee
Institute in Macon County, Alabama, an area known as the "'Black
Belt' because of its rich soil and vast number of black
sharecroppers who were the economic backbone of the region.""
The Tuskegee study, which ended forty years ago, ran from 1932
40. See U.S. Public Health Service Syphilis Study at Tuskegee, CENTERS FOR
DISEASE CONTROL & PREVENTION, http://www.cdc.gov/tuskegee/index.html (last
visited Sept. 19, 2011).
41. Meghna Ranganathan & Raj Bhopal, Exclusion and Inclusion of Nonwhite
Ethnic Minority Groups in 72 North American and European Cardiovascular
Cohort Studies, 3 PLoS MED. 329, 331 (2006).
42. See, e.g., U.S. Public Health Service Syphilis Study at Tuskegee, supra note
40.
43. Marcia Killien et al., Involving Minority and Underrepresented Women in
Clinical Trials: The National Centers of Excellence in Women's Health, 9 J.
WOMEN'S HEALTH & GENDER-BASED MED. 1061, 1063 (2000). "In the 1800s, for
example, Dr. J. Marion Sims, the father of modern gynecology, specifically
purchased [B]lack African slaves to perfect gynecological surgical procedures before
he would try them on white women." Id.
44. Noah, supra note 26, at 229.
45. See U.S. Public Health Service Syphilis Study at Tuskegee, supra note 40.
46. See, e.g., The Tuskegee Study (1930s-1872), INSIDE NAT'L ARCHIVES S.E.
REGION, http://www.archives.gov/southeast/exhibit/6.php (last visited Sept. 22,
2011); U.S. Public Health Service Syphilis Study at Tuskegee, supra note 40.
47. About the USPHS Syphilis Study, TUSKEGEE U., http://www.tuskegee.edu/
about us/centers_of_excellence/bioethics center/abouttheusphs-syphilisstudy.as
px (last visited Sept. 22, 2011).
184 [Vol. 30:179
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through 1972.0 Formally called "Tuskegee Study of Untreated
Syphilis in the Negro Male," the purpose of the study was to
observe the "natural history of Syphilis in Blacks."" The study
included a total of 600 men: "400 [already] syphilitic men,
... [and] 200 uninfected men who served as controls.""
Researchers offered multiple incentives to the participants."
However, the participants were misled about the purpose of the
study. 2
From 1936 through the 1960s, reports on the study were
published every four to six years." An Associated Press reporter
unveiled the study to the media in 1972; when the public learned
of this study they were outraged. 4 The study only ended after the
story went to press." By that time, only 74 of the 600 study
participants were still living, and it is estimated that as many as
100 participants died from their untreated syphilis." In 1974, an
out-of-court settlement was reached in which the United States
"government promised to give lifetime medical benefits and burial
services to all living participants." 7 "The Tuskegee Health Benefit
Program (THBP) was established to provide these services.""
Wives, widows, and offspring of study participants were added as
beneficiaries the following year." Twenty-two years later,
President Clinton issued a public apology.65
48. See U.S. Public Health Service Syphilis Study at Tuskegee, supra note 40.
49. About the USPHS Syphilis Study, supra note 47.
50. Allan M. Brandt, Racism and Research: The Case of the Tuskegee Syphilis
Study, in ETHICAL ISSUES IN MODERN MEDICINE: CONTEMPORARY READINGS IN
BIOETHIcs 727, 727 (Jon-David Hague ed., 6th ed. 2003).
51. About the USPHS Syphilis Study, supra note 47. The participants were
offered "medical exams, rides to and from the clinics, meals on examination days,
free treatment for minor ailments and guarantees that provisions would be made
after their deaths in terms of burial stipends paid to their survivors." Id.
52. See id. "Researchers told the men participating in the study that they were
to be treated for 'bad blood.' This term was used locally by people to describe a host
of diagnosable ailments including but not limited to anemia, fatigue, and syphilis."
Id.
53. Brandt, supra note 50.
54. About the USPHS Syphilis Study, supra note 47.
55. Brandt, supra note 50, at 728.
56. Id.
57. U.S. Public Health Service Syphilis Study at Tuskegee, The Tuskegee
Timeline, CENTERS FOR DISEASE CONTROL & PREVENTION, http://www.cdc.gov/
tuskegee/timeline.htm (last updated June 15, 2011).
58. Id.
59. Id.
60. U.S. Public Health Service Syphilis Study at Tuskegee, Presidential
Apology, CENTERS FOR DISEASE CONTROL & PREVENTION, http://www.cdc.gov/
tuskegee/clintonp.htm (last updated Jun. 15, 2011).
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Unethical research has also been carried out on minorities in
a variety of other settings.6' In the 1950s, Sloan-Kettering
Institute researchers and Ohio State University medical
researchers injected live cancer cells into prisoners at an Ohio
state prison in a National Institutes of Health-sponsored study-
half of the prisoners were Black.6' During the same decade, the
Army and the United States Atomic Energy Commission
sponsored research performed on burn victims at the Medical
College of Virginia.' The burn victims never provided their
consent." The majority of those included in the study were Black
as well. 6' The participants were injected with radioactive isotopes;
in some cases, the amount was fifty times the "maximum
permissible level" for a "normal human being." 66  Holmesburg
Prison in Pennsylvania allowed a study to be conducted in which
prisoners, who were mostly Black, were injected with dioxin, an
incredibly toxic by-product of an herbicide.' Similar to the
Tuskegee Study, many participants stated they had taken part in
the research because it offered incentives, such as money." Often,
researchers either did not tell inmates the entirety of what they
would be exposed to."6 In other situations, the language was so
61. See ALLEN M. HORNBLUM, ACRES OF SKIN 16-17 (1998) (describing the
dangerous scientific experiments conducted on Black prisoners at Holmesburg
Prison in the 1950s).
62. See id. at 93; Mike Adams, Vaccines and Medical Experiments on Children,
Minorities, Woman and Inmates (1845-2007), INFINITE UNKNOWN (Apr. 18, 2010),
http://www.infiniteunknown.net/2008/04/18/vaccines-and-medical-experiments-on-
children-minorities-woman-and-inmates-1845-2007-21.
63. See Public Meeting Before the Advisory Comm. on Human Radiation




65. See HARRIET A. WASHINGTON, MEDICAL APARTHEID 237 (2006).
66. See Public Meeting, supra note 63 (explaining that some study participants
were injected with 500 micro-curies of Phosphorus-32).
67. HORNBLUM, supra note 61, at 163-64, 171-73 (stating that dioxin,
commonly known as Agent Orange, is linked to "cancer, birth defects and fetal
cancer").
68. Id. at 21-23. It seems inmates wanted money for a variety of reasons. One
former inmate said inmates wanted the money 'so they didn't have to wheel and
deal for things." Id. at 23. He also said that the money earned from volunteering
in the experiments "would have been 'really helpful' to him when he left the prison,
if he hadn't squandered it when he was released." Id. Money raised from the
experiments could also help some inmates raise the money needed for bail; they
"could raise the 10 percent bail bond required for freedom." Id. Further, the money
could be used to "hire an attorney . . . before a forthcoming trial[, which] was a
constant preoccupation among these inmates." Id. at 24. Finally, the money could
be used at the prison commissary to buy treats and personal items. Id.
69. Id. at 26-27. Vague language mystified what was actually occurring in the
186 [Vol. 30:179
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technical that the inmates could not understand it." One doctor
who conducted research at the prison, Dr. Klingman, expressed his
excitement for the potential research opportunities at Holmesburg
Prison: "'All I saw before me were acres of skin. It was like a
farmer seeing a fertile field for the first time.' The . . . inmates
... represented a unique opportunity for unlimited and
undisturbed medical research.""
American companies have a history of conducting unethical
research abroad and in United States territories. In a recent
example, Nigerian children and their guardians sued Pfizer,
alleging that the company tested experimental antibiotics on the
children without their consent.72 That case is reminiscent of the
clinical trials that occurred in Puerto Rico during the development
of the birth control pill." In the oral contraceptive trials that
occurred in Boston, "another group [of trial participants] were
given [an] experimental drug without their direct consent." 4 The
oral contraceptives were also tested on twenty-eight male and
female psychiatric patients, which although acceptable by 1950s
standards, would be viewed as unethical today. 5 After the initial
trials in Boston, American researchers looked for a place where
they could conduct larger trials; the researchers settled on the
United States territory of Puerto Rico, where there were plenty of
poor minorities they could exploit."
The women [in one Puerto Rican trial] had only been told that
they were taking a drug that prevented pregnancy, not that
this was a clinical trial, that the Pill was experimental or that
there was a chance of potentially dangerous side effects.
[Scientist Gregory] Pincus and [obstetrician and gynecologist
John] Rock, however, believed they were following the appro-
priate ethical standards of the time. In the 1950s, research
involving human subjects was much less regulated than it is
today. Informed consent standards were minimal and only the
most basic toxicity tests were required for human trials.
research. Id. at 27.
70. Id. Even if given consent forms, many of the prisoners were illiterate and
could not understand them. Id. Consent forms included technical phrases like
"'liver function measures.' 'I couldn't even understand them,' says Weitzman [a
doctor]. 'How would an uneducated inmate?'" Id.
71. Id. at 37.
72. Abdullahi v. Pfizer, 562 F.3d 163, 168 (2d Cir. 2009).
73. See People & Events: The Boston Pill Trials, PBS, http://www.pbs.org/wgbh/
amex/pill/peopleevents/e-boston.html (last visited Oct. 3, 2011).
74. Id.
75. Id.
76. People & Events: The Puerto Rico Pill Trials, PBS, http://www.pbs.org/




A final example of researchers taking advantage of minority
populations was only exposed in late 2010." In this venereal
disease study, American doctors infected almost seven hundred
inmates in Guatemala." American doctors used "prison inmates,
mental patients and soldiers" as the test subjects whom they
injected with sexually transmitted diseases (STDs) and upon
whom they "test[ed] the effectiveness of penicillin.""0  Susan
Reverby unearthed the Public Health Service's (PHS) studies that
took place in Guatemala between 1946 and 1948." PHS
researchers used infected prostitutes to have intercourse with
study participants and infect them with STDs." Researchers
inoculated other participants with tissue from humans or animals
infected with syphilis." The researchers administered penicillin
once they were satisfied with the amount of information collected
from the subject.' Secretary of State Hillary Rodham Clinton and
Health and Human Services Secretary Kathleen Sebelius
immediately issued an apology to Guatemala, as well as study
survivors and their descendants.'
The aforementioned studies are just a small sample of the
manipulation of minorities that has occurred in clinical research in
the past." The ability of researchers to exploit inmates and
working men shows that particular attention needs to be paid to
disadvantaged groups. Requiring researchers to be competent in
cultural distinctions can help to protect those populations.
2. Minority Response
Due to the dark history of manipulation in clinical trials,
many minorities are still reluctant to take part in clinical trials.'
78. Donald G. McNeil, Jr., U.S. Apologizes for Syphilis Tests in Guatemala,
N.Y. TIMES, Oct. 2, 2010, at Al.
79. Id.
80. Id.
81. Susan M. Reverby, "Normal Exposure" and Inoculation Syphilis: A PHS
"Tuskegee" Doctor in Guatemala, 1946-48, 23 J. POL'Y HIST. 6, 6-9 (2011).
82. Id. at 13-15.
83. Id.
84. Id. at 17.
85. McNeil, supra note 78.
86. See, e.g., WAYNE D. LEBARON, AMERICA'S NUCLEAR LEGACY 99-100 (1998)
(describing radiation experiments that were carried out on poor cancer patients for
eleven years, the majority of whom were Black).
87. See Virk, supra note 1.
88. See Amanda Gardner, Black Americans Still Wary of Clinical Trials, U.S.
NEWS & WORLD REP. (Jan. 14, 2008), http://health.usnews.com/usnews/health/
healthday/080114/black-americans-still-wary-of-clinical-trials.htm.
188 [Vol. 30:179
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There is a lot of mistrust, especially in Black communities, of
clinical trials and researchers." This result is problematic
because inclusion of a diverse population sample is imperative to
achieving complete test results and applying them to different
segments of the population.90
One of the main barriers to getting minorities to participate
is a lack of knowledge about the process of clinical research."
Other barriers include "financial issues [and] lower rates of
referrals to research protocols from clinicians."9 2 It is not solely a
reluctance of minorities to participate; occasionally there are
external factors influencing participation.93 For example,
"pharmaceutical companies sometimes discourage the recruitment
of diverse subject populations."
Moving forward, policies and strategies must be developed to
increase minority participation and achieve more equal
representation in clinical research.95 It is especially important
because research has found that Blacks suffer from certain health
problems at a higher rate than Whites.96 Further, without
increased minority participation in research, "exacerbatled] trends
of poorer minority health" could result." The history of mistreat-
ment of minorities in clinical trials has revealed ways to protect
patients and clinical trial participants." Researchers can
89. See Killien et al., supra note 43, at 1064 ("In communities of color, past
injustices and exclusion from the health professions have created explicit feelings of
distrust. Some patients are reticent to make decisions about diagnostic strategies
and treatment without discussing the decision with family and friends."); Gardner,
supra note 88 ("Black Americans continue to distrust medical research and clinical
trials, apparently a lasting legacy of the infamous Tuskegee experiment which was
shut down more than three decades ago, a new study shows.").
90. See Svensson, supra note 39, at 263.
91. See Killien et al., supra note 43. Compounding the problem is the fact that
minority populations are "vulnerable to exploitation." Noah, supra note 26, at 224.
92. Noah, supra note 26, at 225.
93. Id. at 227.
94. Id.
95. See id. at 224 ("[TIhe research community must proceed with caution in any
efforts to equalize participation, both because of the inherent risks of medical
research to individual participants and because some efforts at racial inclusion may
have unintended negative consequences."); Svensson, supra note 39, at 263.
96. Noah, supra note 26, at 223 (asserting that Blacks have a higher rate of
complications from diabetes and certain cancers). This phenomenon also occurs in
some other minority populations besides Blacks. See id.
97. Id. at 225.
98. See 44 Fed. Reg. 30,644 (May 25, 1979) ("By publishing the Report in the
Federal Register, and providing reprints upon request, the Secretary intends that it
may be made readily available to scientists, members of Institutional Review
Boards, and Federal employees."); THE NAT'L COMM'N FOR THE PROT. OF HUMAN
SUBJECTS OF BIOMEDICAL & BEHAVIORAL RESEARCH, DHEW PUBLICATION No. (OS)
20121 189
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overcome the chasm created by bad clinical trials of the past by
increasing diversity in current clinical trials." The present lack of
inclusion hinders complete medical research and can only be
overcome by including minorities in trials. However, attempting
to include minorities is not enough. Special attention needs to be
paid to how culture will affect a potential participant's willingness
to participate.
C. Laws and Ethics Codes To Prevent Unethical
Experimentation
The Nuremberg Code" was promulgated as a result of
unethical experiments performed on concentration camp
prisoners.' 0 The Nuremberg Code supplies a number of ethical
principles for researchers to abide by. o2 One of the main focuses of
the Nuremberg Code is the necessity of receiving voluntary
consent from participants."0 ' The Nuremberg Code was made in
an attempt to prevent further unethical research on human
subjects, but it was not a law."' Therefore American researchers
were not required to abide by it, and in fact, some did not.'05
The Declaration of Helsinki is a more recently drafted code of
ethics that also does not have legal force, but sets out ethical
principles for research." The Declaration emphasizes research-
ers' duty to consider the health and well-being of their patients, as
well as the necessity of voluntary and informed participation. o0
Both ethical codes inspired Title 45, Part 46 (Protection of Human
87-0012, BELMONT REP. (1979) [hereinafter PROT. OF HUMAN SUBJECTS]. The
Belmont Report was initiated just after the Tuskegee Study and established basic
ethical guidelines and principles concerning studies on human subjects. See PROT.
OF HUMAN SUBJECTS, supra.
99. See Svensson, supra note 39, at 265 (arguing that clinical trials will have
greater accuracy and yield more meaningful results if there is increased minority
participation in clinical drug trials).
100. Office of Human Subjects Research, Regulations and Ethical Guidelines,
Nuremberg Code, NAT'L INSTS. HEALTH, http://ohsr.od.nih.gov/guidelines/
nuremberg.html (last visited Oct. 19, 2011).
101. People & Events: The Nuremberg Trials, PBS, http://www.pbs.org/wgbh/
amex/nuremberg/ (last visited Oct. 19, 2011).
102. See Office of Human Subjects Research, supra note 100.
103. Id.
104. See HORNBLUM, supra note 61, at 234.
105. Id. at 234-36.
106. See WORLD MED. Ass'N, DECLARATION OF HELSINKI - ETHICAL PRINCIPLES
FOR MEDICAL RESEARCH INVOLVING HUMAN SUBJECTS (2008), available at
http://www.wma.net/en/30publications/10policies/b3/17c.pdf.
107. Office of Human Subjects Research, Regulations and Ethical Guidelines:
World Medical Association Declaration of Helsinki, NATL INSTS. HEALTH,
http://ohsr.od.nih.gov/guidelines/helsinki.html (last modified Sept. 10, 2004).
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Subjects) of the United States Code of Federal Regulations."o' The
Declaration is still considered extremely important and relevant.
"[Tihe World Medical Association's Declaration of Helsinki ... sets
forth ethical principles to guide physicians world-wide and
provides that human subjects should be volunteers and grant their
informed consent to participate in research.""
[The Declaration] enunciate[s] standards for obtaining
informed consent from human subjects. It provide[s] that in
clinical research combined with professional care, "[i]f at all
possible, consistent with patient psychology, the doctor should
obtain the patient's freely given consent after the patient has
been given a full explanation," and that non-therapeutic
clinical research on a person "cannot be undertaken without
his free consent, after he has been fully informed."1 o
The Declaration's discussion of the necessity of informed written
consent and ethical treatment of research participants gives it an
important place in clinical research."'
II. Informed Consent
A. Background and Development
One of the first constructions of the theory of informed
consent can be found in a 1957 case." 2 Initially it was discussed in
jury instructions detailing a duty to disclose."' The doctrine
108. See 45 C.F.R. § 46 (2009). Part 46, Protection of Human Subjects, is still in
effect today. Id.
[Tihis policy applies to all research involving human subjects conducted,
supported or otherwise subject to regulation by any federal department or
agency which takes appropriate administrative action to make the policy
applicable to such research. This includes research conducted by federal
civilian employees or military personnel, except that each department or
agency head may adopt such procedural modifications as may be
appropriate from an administrative standpoint. It also includes research
conducted, supported, or otherwise subject to regulation by the federal
government outside the United States.
Id. § 46.101.
109. Abdullahi v. Pfizer, 562 F.3d 163, 175 (2d Cir. 2009) (citing the Declaration
as an important factor in the development of the informed consent doctrine to help
protect research participants).
110. Id. at 181.
111. Id. at 181-82.
112. Salgo v. Leland Stanford Jr. Univ. Bd. of Trs., 317 P.2d 170 (Cal. Ct. App.
1957); see also Cathy J. Jones, Autonomy and Informed Consent in Medical
Decisionmaking: Toward a New Self-Fulfilling Prophecy, 47 WASH. & LEE L. REV.
379, 388-89 (1990).
113. Leland Stanford Jr. Univ. Bd. Of Trs., 317 P.2d at 181 (explaining a
doctor's duty to explicate all important facts to patients so they can "form the basis
of intelligent consent ... to the proposed treatment").
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continued to develop over the years."4 The American Medical
Association currently defines informed consent as "[the] process of
communication between a patient and physician that results in
the patient's authorization or agreement to undergo a specific
medical intervention.""'
B. Requirements and Exceptions
"Most consent cases generally focus on whether the consent
was 'informed,' i.e., whether the patient was given sufficient
information to make a decision regarding his or her body and
health care.""6
The general requirements of what information must be given
to patients for valid informed consent for regular medical
treatments include the "problem or diagnosis for which further
investigation or intervention is proposed, . . . the recommended
intervention ... with the significant benefits and risks [involved],
the results or prognosis if no intervention is attempted, and
... any significant alternative[s] . *.. ."'" It is also a requirement
that informed consent be documented on a written consent form."8
Three exceptions to gaining informed consent from competent
patients can be applied: waiver, emergency, and therapeutic
privilege."9 Waiver, which focuses on autonomy, gives patients
the right to forego "their right to give . . . informed consent," with
the requirement that waiver is voluntary and intentional."' The
emergency exception is fairly self-explanatory; if there is an
emergency "a doctor may render treatment without the patient's
consent; consent is said to be implied.""' Therapeutic privilege is
the most well-known exception, applying in a situation in which
informing the patient could somehow cause harm to the patient.122
114. Jones, supra note 112, at 389-96.
115. Patient Physician Relationship Topics: Informed Consent, AM. MED. Ass'N,
http://www.ama-assn.orglama/pub/physician-resources/legal-topics/patient-
physician-relationship-topics/informed-consent.shtml (last visited Sept. 22, 2011).
116. Id.
117. STEPHEN WEAR, INFORMED CONSENT: PATIENT AUTONOMY AND CLINICIAN
BENEFICENCE WITHIN HEALTH CARE 10 (1998); see 21 C.F.R. § 50.23 (2011).
118. 21 C.F.R. § 50.27.
119. See JESSICA W. BERG ET AL., INFORMED CONSENT: LEGAL THEORY AND
CLINICAL PRACTICE 75-125 (2d ed. 2001).
120. Id. at 85.
121. Id. at 76.
122. See id. at 79. For example, suppose a doctor withholds from the patient the
medical name for an illness because of the stigma attached to it. "Insisting that
[the] patient hear the name of [the] condition, at the likely cost of failing to ensure
that [he/]she understands what [he/]she needs to do to help improve [his/Jher
192 [Vol. 30:179
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Consent must be obtained if feasible.'" It is considered unfeasible
if it can be certified in writing that four provisions apply: it is a
life threatening situation; the patient is unable to communicate;
there is insufficient time to obtain consent from the patient's legal
representative; and there are no approved or generally recognized
alternative therapies to save the patient's life.'24 The concept of
informed consent is also codified in statutes.125
Other regulations provide that informed consent must be
obtained from each research participant and the participant must
have an "[o]pportunity to consider whether or not to participate" in
the research."2 In addition, the researchers have to "minimize the
possibility of coercion or undue influence" of the research
participants.1 2 1 It is well accepted that if a study participant
speaks a language other than English, information must be given
in the language the participant speaks and understands.128 If the
information is given to the participant in a language he or she
understands, the requirements of informed consent have been
satisfied.129 There are, however, other factors to be considered.''
C. Cultural Beliefs, Informed Consent, and Clinical
Research
As stated above, researchers continue to encounter difficulty
recruiting minorities and diverse populations for clinical research
situation, would be harmful." Matthew Wynia, Invoking Therapeutic Privilege,
VIRTUAL MENTOR, Feb. 2004, available at http://virtualmentor.ama-assn.org/2004/
02/msocl-0402.html.
123. 21 C.F.R. § 50.23.
124. Id.
125. See, e.g., 21 U.S.C. § 355 (2006). Section 355 reads:
[R]equiring that experts using . . . drugs for investigational purposes
certify ... that they will inform any human beings to whom such drugs, or
any controls used in connection therewith, are being administered, or their
representatives, that such drugs are being used for investigational
purposes and will obtain the consent of such human beings or their
representatives, except where it is not feasible or it is contrary to the best
interests of such human beings.
Id.




130. For example, the patient's health literacy should be considered. A problem
with the approach of only requiring provision of information in a patient's
language, is that an "individual's ability to read and comprehend health-related
materials, such as medication instructions and informed consent forms, may be
substantially weaker than [his or her] general literacy." Noah, supra note 26, at
228.
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studies. First, a lack of trust of researchers and a low
understanding of the process creates a barrier to reaching diverse
populations."' Also, language barriers make it more difficult for
researchers to give notice to minority communities as researchers
seek to diversify studies.13' Finally, researchers are less inclined
to include populations with language barriers because of the need
for translators and interpreters, along with the difficulties in
following-up with participants.33
The focus of this Article is on the lesser known cultural
aspects involved with including minorities in clinical research.
"Cultural differences ... lead to miscommunication and misinter-
pretation of actions and motives, among both potential study
participants and investigators."134  Many minority groups have
differing views on health care and its specific role in their
culture."' For example, in the Hispanic community, family is
extremely important, as are respect and personal relationships."'
Additionally, Hispanic communities embrace concepts such as
espiritismo and fatalismo."' Other variations are seen in the
Hmong population." The Hmong have a culture in which
shamans are very important and the language has few medical
terms; they believe in spiritual healings and herbal treatments. 39
Many Ethiopians believe in a strong connection between "the body
and the outside," often attributing illnesses to an exterior cause."'
131. See Killien et al., supra note 43; supra Part I.B.ii.
132. See Janet D. Stemwedel, Language Barriers and Human Subjects Research,
ADVENTURES ETHICS & SCI. (Feb. 23, 2009, 7:08 PM), http://scienceblogs.com/ethics
andscience/2009/02/language_.barriers andhuman su.php.
133. E-mail from Sara DeSanto, supra note 8.
134. Killien et al., supra note 43.
135. See Robert J. Blendon et al., How White and African Americans View Their
Health and Social Problems, 273 JAMA 341, 341 (1995).
136. Ross Mullner & Aida L. Giachello, Traditional Health and Disease Beliefs,
Access to Health Care, Cultural Sensitivity, HEALTH, http://www.jrank.org/cultures/
pages/3951/Health.html (last visited Sept. 20, 2011) (archival version on file with
author but no longer available on the Internet).
137. Id. Espiritismo is described as "view[ing] health synergistically as a
continuum of mind, body, and espirtu (spirit). Illness symptoms are derived from
this continuum. Mental health problems and psychosocial stress are likely to
appear as somatic complaints." Id. Fatalismo is the belief "that disease is a
punishment sent by God . . . for wrongdoings. Therefore, many Hispanics believe
that suffering from a disease must be accepted and endured by the individual." Id.
138. See STRATIS HEALTH, CULTURE MATTERS: INFORMATION ON HMONG
CULTURE AND HEALTH CARE 2 (2006), available at http://www.stratishealth.org/
documents/CCHmong_121907.pdf.
139. Id. at 1-2.
140. Richard M. Hodes, Cross-Cultural Medicine and Diverse Health Beliefs:
Ethiopians Abroad, 166 W. J. MED. 29, 29 (1997).
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These few examples illustrate how views of health care can differ
between cultures. Understanding the differences is imperative in
clinical research as well as in implementing successful health
care."' Although cultural nuances have yet to be addressed in
clinical research, steps have been taken to avoid unethical and
unjust treatment.14 2
III. Laws and Policies To Increase Minority Inclusion and
Ethical Treatment
A. National Research Act and the Belmont Report
The National Research Act was passed in 1974 and created
the National Commission for the Protection of Human Subjects of
Biomedical Research.'" The Commission sought to avoid
replicating past injustices in human experimentation by
identifying ethical principles to guide future researchers.'" A few
years later, the Belmont Report was created, compiling the
Commission's findings. 45  The Belmont Report is a policy
statement created after careful thought by eleven legal, medical,
and ethical professionals." "It is a statement of basic ethical
principles and guidelines that should assist in resolving the ethical
problems that surround the conduct of research with human
subjects." 147
B. National Institutes of Health
The National Institutes of Health (NIH) is an agency that
sponsors and funds clinical trials.1 " "NIH is the largest source of
funding for medical research in the world .. . .."' NIH is "a part of
the U.S. Department of Health and Human Services," and is
141. See Jacquelyn C. Campbell et al., Challenges of a Multisite Multicultural
Collaborative Research Endeavor: The Birthweight Study, in DIVERSITY IN HEALTH
CARE RESEARCH: STRATEGIES FOR MULTISITE, MULTIDISCIPLINARY, AND
MULTICULTURAL PROJECTS 145, 147 (Joellen W. Hawkins & Lois A. Haggerty eds.,
2003) (showing the cultural aspect is important because it is "crucial if the outcome
is to lead to knowledge that guides the provision of culturally competent care").
142. See infra Part III.
143. The Belmont Report, HHS.gov, http://www.hhs.gov/ohrp/humansubjects/
guidance/belmont.html (last visited Oct. 2, 2011).
144. Id.
145. PROT. OF HUMAN SUBJECTS, supra note 98.
146. The Belmont Report, supra note 143.
147. See id.
148. Understanding Clinical Trials, supra note 21.
149. U.S. Dep't of Health & Human Servs., About the National Institutes of
Health, NIH.GOV (Oct. 27, 2010), http://www.nih.gov/about/index.html.
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comprised of "27 Institutes and Centers, each with a specific
research agenda . . . ."'s The NIHRA was passed in 1993.151
Through this Act, Congress "made what had previously been policy
into public law."' The Act provided four important additions to
the NIH policies that were in place at the time:
* NIH ensures that women and minorities are included
in all human subject research;
* Phase III clinical trials['I inclusion of Women and
minorities in numbers adequate to allow for valid
analyses of differences in intervention effect;
* Cost is not allowed as an acceptable reason for
excluding these groups; and,
* NIH initiates programs and support for outreach
efforts to recruit and retain women and minorities
and their subpopulations as volunteers in clinical
studies[.]1
The following year, NIH "published [the] NIH Guidelines on
the Inclusion of Women and Minorities as Subjects in Clinical
Research in the Federal Register."" The NIH developed these
guidelines as a response to the requirements of the NIHRA." The
outreach notebook includes factors to consider when including
minorities in clinical research and discusses the necessity of
understanding minority populations.'56
C. FDA
The Investigational New Drug Application section of the
Code of Federal Regulations enables the FDA to review the
applications for investigational new drugs (INDs)."' The FDA has
made efforts to increase minority participation in clinical
research.'" "[T]he Food and Drug Modernization Act of 1997
150. Id.
151. National Institutes of Health Revitalization Act of 1993, 42 U.S.C. § 289a-2
(2006).
152. Nat'1 Insts. of Health, Inclusion of Women in Research, OFF. RES. ON
WOMEN, http://orwh.od.nih.gov/inclusion.html (last visited Oct. 2, 2011).
153. Id.
154. NAT'L INSTS. OF HEALTH, OUTREACH NOTEBOOK FOR THE NIH GUIDELINES
ON INCLUSION OF WOMEN AND MINORITIES AS SUBJECTS IN CLINICAL RESEARCH 1
(1994) [hereinafter NIH GUIDELINES].
155. Id.
156. See id. at 3. Some of the factors include "characteristics of the population of
interest and the settings in which they are encountered." Id. at 1.
157. 21 C.F.R. § 312.1 (2010).
158. B. Evelyn et al., Participation of Racial/Ethnic Groups in Clinical Trials
and Race-Related Labeling: A Review of New Molecular Entities Approved 1995-
1999, 93 J. NAT'L MED. Ass'N 18S, 19S (2001) ("Attention to potential racial and
ethnic differences in response to drugs is part of a larger effort by the FDA to
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(FDAMA) .. .prompted [the] FDA to examine issues related to the
inclusion of racial and ethnic groups in clinical trials."'" FDAMA
"called for the establishment of a clinical trials registry that would
be available to the public," leading to the creation of the
"ClinicalTrials.gov" website.16' The FDAMA also instructs the
FDA to consult with the NIH and other industry members for
guidance to achieve the goal of including more women and
minorities in clinical trials.161
These policies and regulations are a good starting point for
ethically conducted research that is inclusive of diverse
populations. However, carefully planned legislation can help ease
the difficulties of including diverse populations and moving past
cultural barriers.
IV. Suggested Solutions for Clinical Research Legislation
A. Problems with the Current Approach
Currently, no laws specifically require minorities to be
included in all clinical research.'" Furthermore, legislation and
guidelines do not address the cultural differences that play an
important role for many minority populations.'" Although there
are regulations and laws in place that encourage or require
participation, loopholes allow researchers to avoid the requirement
of including minorities in their research.
The NIHRA is an example of seemingly complete legislation
that contains loopholes that allow manipulation." One provision
ensure that the safety and efficacy of drugs are adequately studied in people who
represent the full range of patients who will receive them upon marketing.").
159. Id.
Section 505(b)(1) (21 U.S.C. 355(b)(1)) is amended by adding . . .: "The
Secretary shall, . . . with the Director of the [NIH] and with
representatives of the drug manufacturing industry, review and develop
guidance ... on the inclusion of... minorities in clinical trials ....
Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105-115, 111
Stat. 2296.
160. Mary Fitzgerald, Advocate for Access to Medical Data: Linguist Wants
Patients To Understand, WASH. POST, July 28, 2004, at A17.
161. Richard A. Merrill, Modernizing the FDA: An Incremental Revolution, 18
HEALTH AFF. 96, 100 (1999), available at http://content.healthaffairs.org/contentl
18/2/96.full.pdf.
162. See National Institutes of Health Revitalization Act of 1993, 42 U.S.C.
§ 289a-2 (1993); 111 Stat. 2296. Neither the NIH Revitalization Act nor the Food
and Drug Administration Modernization Act require minorities to be included in all
clinical studies. See 42 U.S.C. § 289a-2 (1993); 111 Stat. 2296.
163. See, e.g., 111 Stat. 2296 (failing to include cultural differences in its
requirements for clinical trials).
164. See 42 U.S.C. § 289a-2.
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contains an exception stating that minorities do not have to be
included if the researchers can show that there would be no
significant difference between the results the researchers would
obtain from a minority participant and the participants they plan
to include.16' However, it might be difficult for a researcher to
show that the variables will not impact the races differently if they
are researching a novel condition, disease, or medication."
If researchers are making relatively minor changes to the
medication or treatment, and before those changes, insignificant
differences resulted among the races, it still could be useful to
know how the new changes would differently impact various
subsets of the population. To obtain that information, minorities
should be included in the research and cultural differences should
be a factor used in communicating with participants, conducting
the research, and applying the results. 67
Regulators must strike a balance. Though clinical
researchers should retain the ability to comply with the NIHRA,
loopholes that automatically qualify clinical research as suitable
should be eliminated." Unless specifically tailored to a certain
race, clinical researchers should be encouraged to include a variety
of cultures in their clinical research, no matter how similar they
think the results might be.'69
Additionally, clinical researchers often incorrectly equate the
inclusion of minorities with cultural variety.17o Many different
cultures can exist within one minority population."' Differences
in medical practices, family roles, and other factors such as what
each culture perceives as an illness exist in different minority
cultures. 172 The lack of consideration and legislation directing
researchers to consider these factors can make it more difficult for
165. Id. § 289a-2(d)(2)(B).
166. See Mayo Clinic Staff, Clinical Trials: A Chance To Try Evolving Therapies,
MAYOCLINIC.COM (July 2, 2011), http://www.mayoclinic.com/health/clinical-
trials/DIO0033. The purpose of clinical trials is to test new medications or research
new diseases to learn more about them. See id.
167. See Campbell et al., supra note 141.
168. See 42 U.S.C. § 289a-2(d)(2)(B).
169. See, e.g., Deborah S. Smith et al., Racial Differences in a Prostate Cancer
Screening Study, 156 J. UROLOGY 1366, 1366 (1996) (stating results of a study of
White and Black men showed that Black men had a less than two percent higher
chance of prostate cancer).
170. See Campbell et al., supra note 141 ("Investigators need to give serious
consideration to the role of cultural factors and avoid assuming that identity with
the minority culture is defined by the person's race or surname.").
171. See Leonard E. Egede, Race, Ethnicity, Culture, and Disparities in Health
Care, 21 J. GEN. INTERNAL MED. 667, 667 (2006).
172. See Mullner & Giachello, supra note 136.
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researchers to connect and build trust with participants.173  The
FDA has the right end goal in mind: to encourage adequate
minority participation.'74  However, a greater understanding of
minority cultures is also necessary for successful and more
complete research."' There are some enrollment issues, in part
because of the role culture plays in a potential participant's
decision-making."' Once the medical community acquires a
proper understanding of cultural factors' influences, physicians
will be better able to understand how to effectively treat their
patients.
B. Cultural Focus in Clinical Research Participants
Currently there is a lack of legislation focused on the cultural
aspects of participants in clinical trials.'77 Cultural differences can
lead to different results with medications or illnesses,78 but the
lack of legislation and regulations addressing these variables
allows clinicians to ignore such factors. A difference in culture can
affect how participants and the public view doctors and
medicine."' Foundational beliefs greatly affect medical
application, and truly make a difference. The Chaplain involved
in a case where a pregnant woman from Central America was
diagnosed with leukemia said that:
173. See WASHINGTON, supra note 65.
174. See Food and Drug Administration Modernization Act of 1997, Pub. L. No.
105-115, 111 Stat. 2296.
175. Campbell et al., supra note 141.
176. See WASHINGTON, supra note 65, at 180 (discussing "African Americans'
aversion to the health-care system"). Blacks are still reluctant to participate due to
the history of Blacks in the health care system: "a centuries-old pattern of
experimental abuse. . . ." Id. at 180-81.
177. Regulations, FDA (Nov. 26, 2010), http://www.fda.gov/scienceresearch/
specialtopics/runningclinicaltrials/ucml55713.htm. The FDA's website lists laws
and regulations surrounding clinical trials, and none of them contain requirements
of consideration of cultural factors. Id. Only three states have enacted mandatory
legislation: California, New Jersey, and Washington. Mary Nakashian, Studying
State Legislation of Cultural and Linguistic Competence, ROBERT WOOD JOHNSON
FOUND. (Oct. 2009), http://www.rwjf.org/reports/grr/059024.htm.
178. See Interview with Ralph Hall, Teaching Specialist, Univ. of Minn. Law
Sch., in Minneapolis, Minn. (Oct. 20, 2010). This can occur because some cultures
will not take medication as prescribed or will use different treatments for illness.
Id. If a researcher has an understanding of this occurrence, he or she can tailor the
research process when necessary to increase the likelihood of accurate results. Id.
179. See, e.g., WASHINGTON, supra note 65, at 180 ("The Tuskegee Syphilis Study
ended a quarter of a century ago, but its effects can still be felt .... 'Many African
Americans' distrust in today's medical establishment can be attributed to
Tuskegee.' (quoting Deborah Shelton, Mistrust of Doctors Lingers After Tuskegee;
Many Blacks Remain Wary-and Underserved-a Quarter Century After Infamous
Syphilis Study, WASH. POST, Apr. 15, 1997, at Z8)).
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[W]e could have done a better job [from a cultural perspective]
.... We're talking about foundational beliefs and about
comfort-not the medical comfort, but comfort with the space,
the presence, the people. Think about if we were receiving our
end-of-life care in [Latin America], surrounded by Spanish-
speaking people. .. .'8o
Because of such differences, some cultures might be excluded
or tend to self-exclude themselves from clinical research.'" For
example, breast cancer mortality is higher among Black women
than White women, yet the "incidence [of breast cancer] is
somewhat lower among [Black] women."'8 2 Socioeconomic factors
influence when patients receive medical attention for breast
cancer, but "[c]ultural factors such as beliefs, attitudes, and
knowledge about cancer are also known to vary dramatically by
race, and the importance of these cultural factors is increasingly
recognized."'" Lannin's breast cancer study determined that some
of the cultural factors that influenced at which stage breast cancer
patients were diagnosed included "health care utilization, folk
beliefs, relationships with men, perceived risk or fatalism, [and]
belief in various treatments. . . ."'" The same phenomenon
translates into clinical trials as well; cultural factors will impact
medical diagnoses and presentation of symptoms, side effects,
patient comfort and drug reactions.'" Also, with different
cultures, especially when a participant speaks a foreign language,
patients' perception of autonomy might be skewed."
180. Alexander K. Smith et al., Palliative Care for Latino Patients and Their
Families, 301 JAMA 1047, 1048 (2009).
181. See WASHINGTON, supra note 65, at 180. Many Blacks still distrust doctors
and medical establishments due to the negative history, resulting in many Blacks
self-excluding. See id.
182. Donald R. Lannin et al., Influence of Socioeconomic and Cultural Factors on
Racial Differences in Late-Stage Presentation of Breast Cancer, 279 JAMA 1801,
1801 (1998).
183. Id. (citation omitted).
184. Id. at 1804. Furthermore, "[women who held any of the culturally derived
folk beliefs, fundamentalist religious beliefs, or beliefs about relationships with
men or fatalism were all significantly more likely to present with late-stage
disease." Id.
185. See Interview with Ralph Hall, supra note 178.
186. See Andrew Fagan, How Autonomous Is Medical Decision Making?, 11 AM.
MED. ASS'N J. ETHics 631, 633-34 (2009).
The more deeply an individual is formed by . .. culture, the more difficult
it will be to recreate his or her identity in an alternative existential
setting. The depth of an individual's integration within some communities
and the absoluteness of that community's ethical prescriptions can
severely restrict the individual's capacity to exercise choice . ...
Id.
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Legislation addressing cultural factors in clinical research
can allow the participant and researcher to lower the barriers to
entry.' The consideration of cultural factors will eventually
become a necessity due to the changing cultural makeup of the
United States.'" FDAMA and NIHRA are the first steps in
addressing the inclusion of minorities in clinical research. 89
Attributing various reactions and disease prevalence rates to
certain races and ethnicities is crucial to properly addressing
clinical research and interpreting results.190 Furthermore,
determining the risk factors for certain diseases that are
associated with particular racial or ethnic groups can enable the
medical community to better-tailor health care for individual
patients.
Cultural beliefs greatly impact how a person interprets
symptoms.'92 Without considering cultural identity in research
studies, it is possible that researchers will overlook factors
imperative to their research or will misinterpret results. 93 For
example, symptoms might manifest themselves differently due to
varied cultural interpretations of what a symptom represents,
risking misinterpretation of results.94
187. See Campbell et al., supra note 141. "Some reliable and valid means of
assessing subjects' degree of identification with their own culture greatly enhances
the research. Assessing the role of factors such as assimilation, country of origin,
and migratory status is important." Id.
188. See U.S. Minorities Will Be the Majority by 2042, Census Bureau Says,
AMERICA.GOV (Aug. 15, 2008), http://www.america.gov/st/diversityenglish/2008/
August/20080815140005x1rennef0.1078106.html.
189. See National Institutes of Health Revitalization Act of 1993, 42 U.S.C.
§ 289a-2 (2006); Food and Drug Administration Modernization Act of 1997, Pub. L.
No. 105-115, 111 Stat. 2296.
190. See Ctrs. for Disease Control & Prevention, General Refugee Health
Guidelines, CDC.GOV (Aug. 23, 2010), http://www.cdc.gov/immigrantrefugeehealth/
guidelines/general-guidelines.html. For example, Hmong have a higher prevalence
of gout. See Interview with Ralph Hall, supra note 178.
191. See WASHINGTON, supra note 65, at 314-15. "[Bl1ack women .. . have a
higher-than-normal risk of the BRCA, gene, which confers as much as a 70 percent
higher risk of breast cancer . . . ." Id. "African Americans and Hispanics living in
Manhattan . . . harbor a genetic variant (APOE-epsilon) that places them at a
higher relative risk of developing Alzheimer's disease than [Whites." Id. at 315
(citations omitted). Some of the factors can be extremely important for clinical
studies, such as in the case of "African Americans . . . [being] more likely than
[Wihites to be healthy carriers of glucose-6-phosphate dehydrogenase (G6PHD)
syndrome, which can cause the loss of red blood cells and affects many medical
risks and medication reactions." Id. (citations omitted).
192. Campbell et al., supra note 141, at 151.
193. See id.
194. Id.
[Tihe list of symptoms . . . and interpretations associated with it are
attempts to capture and categorize . . . ways that people experience or
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Recognizing that a lump is growing and becoming bothersome
... does not necessarily imply that a woman will seek medical
treatment for it. The majority of patients with late-stage
presentation believed that "letting air get to a cancer" or
"cutting on a cancer" was to be avoided because it would cause
the cancer to spread. Instead, many advocated the use of
alternative treatments ... prayer and a reliance on God to
heal the disorder.19 5
If a patient or participant is afraid of discussing or exposing
symptoms he or she is experiencing, it can become a danger to the
health of the patient or participant.96
Safety and dialogue are primary concerns for researchers
understanding how different cultures interpret symptoms. 97
Requiring researchers to use translators and interpreters is a first
step to achieving cultural variety." Occasionally, however,
relevant information is lost in translation." "Language fluency is
not a yes-or-no skill but a spectrum that includes facility of
language, familiarity with medical terminology, and under-
standing of cultural context. An imbalance between speaking
ability and understanding may lead to situations in which
clinicians can ask simple questions in Spanish, but not understand
complex responses."2 00 This leads to the question, what are
researchers "excluding such that risks and benefits are difficult to
determine for the population?"2 0 1 Excluding important cultural
nuances in clinical research could lead to negative or problematic
reactions to the product.202 Though translation and interpretation
are imperative for clinical research, other cultural factors must be
considered as well. 203
report their experience. The experiences on which most instruments are
based are usually of. . . Euro-American origin . . . . [Djifferent experiences
and different languages may engender different manifestations of distress
or wellness.
Id.
195. Lannin et al., supra note 182, at 1806.
196. Eunice Kennedy Shriver, Nat'l Inst. of Child Health & Human Dev., What
Else Should I Know About Clinical Research?, NAT'L INSTS. HEALTH (June 24,
2010), http://www.nichd.nih.gov/health/clinicalresearch/aboutclinicalresearch.cfm.
197. See Campbell et al., supra note 141, at 151.
198. Understanding Clinical Trials, supra note 21.
199. Killien et al., supra note 43.
200. Smith, supra note 180, at 1050.
201. Interview with Ralph Hall, supra note 178.
202. Id.
203. Killien et al., supra note 43 (supporting the opinion presented in this Article
that translation itself does not accomplish the necessity of adequate inclusion of
minority populations).
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The perception of power is another important factor when
approaching cultural differences. Cultural norms and power
hierarchies are an important aspect of cultural familiarity."*
Sometimes decision-making power resides with the individual,
while other times it is with family members or other community
members.205
A further consideration when addressing patient care,
especially in clinical trials, is cultural autonomy.206 How much a
participant identifies with his or her culture should determine how
to approach that patient.20' A particular study participant might
not identify with all aspects of his or her culture, which could
mean culture has less of an impact on his or her participation in
the study.208 If a person identifies closely with his or her culture,
how much autonomy does he or she have?200 Some questions might
be: whether or not he or she makes his or her own medical
decisions; how other decisions are made within his or her culture;
the importance of family; and in some cases, the male and female
power relationship.21 0 If researchers know what questions to ask
and what patients view as important, they will be able to better
communicate with patients and therefore obtain more accurate
results.211
204. See Hispanic Healthy Marriage Initiative, Gender Norms and the Role of
the Extended Family, DEP'T HEALTH & HUMAN SERVICES ADMIN. FOR CHILD. &
FAMS. 2, http://www.acf.hhs.govlhealthymarriage/pdflGender Norms.pdf (last
visited Oct. 2, 2011). Historically, in Hispanic families, men hold control while
women tend to be more submissive; extended family is seen as very important. Id.
Although these are seen as the traditional roles and still impact many
relationships, this generalization should not be made to all families today. Id.
205. See, e.g., Smith et al., supra note 180, at 1054 (stating that in the Hispanic
community, women are responsible for health issues within their families).
206. See Interview with Ralph Hall, supra note 178. "Legal scholars define
cultural autonomy as 'the right to self rule, by a culturally defined group, in regard
to matters which affect the maintenance and reproduction of its culture.'" STEVEN
C. ROACH, CULTURAL AUTONOMY, MINORITY RIGHTS, AND GLOBALIZATION 3 (2005).
207. See Sylvestre Quevedo, Culture and Medicine: Reflections on Identity and
Community in an Age of Pluralism, PERMANENTE J., Winter 2008, at 63, 64-65.
Quevedo gives a definition of culture "as 'a shared system of values, beliefs, and
learned patterns of behavior.'" Id. at 64 (citations omitted).
208. See id. This could be equated with religion; not every person identifies or
agrees with every single tenet of his or her religion. Quevedo, quoting Jerome
Bruner, puts it sensibly: "to be part of a culture is to be 'bound in a set of
connecting stories, connecting even though the stories may not represent a
consensus.'" Id. (emphasis in original) (citations omitted).
209. Id. at 64-65.
210. See Mullner & Giachello, supra note 136.
211. See Campbell et al., supra note 141, at 151; Lowanda Dent, The Role of
Cultural Competency in Eliminating Health Disparities, MINORITY NURSE, Winter




C. Suggesting New Legislation
To correct the inequality created by ignoring cultural factors
in clinical research, legislation must be passed that can begin to
remedy the problem. When the bill is proposed it must be
considered carefully and in collaboration with agencies possessing
necessary expertise. Agencies often possess the knowledge
necessary to determine the importance of accounting for cultural
variety in research.212 Furthermore, some studies focus on a
particular subset of the population by design, so legislation should
be drafted to reflect this.213 By including agency expertise in new
legislation, it will help to make sure that legislation includes
plausible changes as well as the crucial specificity.
1. Potential Language of New Legislation
The legislation drafted should include a provision stating
that cultural factors must be considered. Researchers are often
reluctant to include minorities in research because language
barriers, comprehension problems, and other difficulties make
researchers' tasks more complicated.21' To ease compliance, the
legislation should provide researchers with comprehensive
guidance. Such guidance could include the factors that should be
considered when addressing cultural competence and the sites
that should be consulted in determining a culture's approach to
medical care.21
While in an ideal world a variety of cultures would be
included in every clinical research study, it is impracticable to
require such uniform inclusion. Occasionally, a specific study will
not necessitate inclusion of all minorities and cultural factors in
research-for example researching how a medication will affect a
particular race.2 " The legislation should reflect those exceptions,
but be extremely specific so as not to create unnecessary loopholes.
Careful thought should be given to the statute's list of exceptions
212. See NIH GUIDELINES, supra note 154, at 25 (outlining federal agencies able
to assist clinical investigators).
213. See Ranganathan & Bhopal, supra note 41, at 332 (discussing the history of
studying "ethnic variations in disease").
214. See Stemwedel, supra note 132.
215. See NIH GUIDELINES, supra note 154, passim (discussing factors to be
considered in including minorities and women in clinical experimentation).
216. See WASHINGTON, supra note 65, at 315 (discussing differences of medical
conditions between certain races in Manhattan). If researchers wanted to
specifically focus on a reaction that occurs in one race that has already been
studied in a diverse environment, it would not necessitate including a diverse
cultural makeup. See OUTREACH NOTEBOOK, supra note 4, at 22.
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to avoid further problems such as the manipulation of
ambiguities."'
Legislation requiring cultural consideration in clinical
research will provide an avenue through which clinical researchers
can ensure fairness and equality. Furthermore, this legislation
will provide an impetus for researchers to become aware of
cultural considerations. This awareness will eventually become
second nature to researchers.2 18 A further method of ensuring
cultural factors are accounted for would be to have a cultural
expert available to researchers. This expert could tell researchers
necessary and pertinent information about the populations who
are participating in their study.2 19 An example of possible
language incorporating these ideas is:
When including various cultures in research, researchers must
consider cultural factors and their impact on results by
consulting a cultural expert or achieving cultural competency
in another matter approved by the [FDA or NIH]. Researchers
are not required to include an array of cultures if studying the
impact of a medication or procedure on a specific subset of the
population, or when following up on specific results within a
population of a previous study that included a variety of
cultures.
The cost of implementing this legislation is another concern.
Time and money will be necessary for researchers to become
culturally competent. 2 2 0  Due to the cost and current unstable
economic conditions in the United States, such implementation
will probably not be immediate.2 2 ' However, the sooner steps are
taken to implement these changes and require incorporation of
cultural factors, the sooner that better and more accurate results
can be expected.
217. See supra Part W.A. The exceptions in NIHRA do not provide enough
specificity to avoid giving researchers the ability to comply with the Act while still
excluding minorities. See National Institutes of Health Revitalization Act of 1993,
42 U.S.C. § 289a-2 (2006).
218. Cf Killien et al., supra note 43, at 1068-69 (asserting that increased
inclusion of "underrepresented groups" will improve understanding achieved
through clinical research).
219. Cf NIH GUIDELINES, supra note 154, at 14 (arguing that advisory boards
can guide recruitment of individuals from certain cultures to clinical research
studies).
220. Acquiring the knowledge will not happen immediately, but over time
researchers can incorporate the ability to work cultural differences into their
knowledge base. See Judith A. Lewis, Foreword to DIVERSITY IN HEALTH CARE
RESEARCH, supra note 141, at xi (arguing that "learned knowledge, skills, and
abilities" are critical to ensuring cultural sensitivity in clinical experimentation).
221. For example, Cohen, supra note 13, at 2, noted that "in 2005 the federal
government spent about $1.5 billion on all health services research. . . ." This level
of expenditure would be unlikely in today's economic climate.
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2. Uniform State Laws Versus Federal Law
Legislation could be passed at the federal level, or a uniform
law could be drafted for states to pass individually. Uniform laws
are a model that states are encouraged to adopt individually.
Once adopted, they become law in that state.22 For a variety of
reasons, state-by-state adoption of a model law is not the best
direction to take the legislation.22 3 Not every state will necessarily
adopt a uniform law, which means states without the requirement
of considering cultural factors in research could become the
location of choice for researchers to get around the new
requirements.224 Additionally, because each state adopts and
codifies the law itself, states can make individual changes to the
law, destroying uniformity.2 " This would make it easier for a state
health agency to oversee the enforcement and application of the
law.
However, a model law would not be the proper approach to
implementing the legislation. The Food and Drug Administration
(FDA) oversees clinical trials. Thus, enforcement and application
should be left to the federal agencies and federal legislature.226
The risk of nonuniformity is too great. A model law would burden
the FDA and NIH with having to consider separate and sometimes
different standards for each state when reviewing clinical
research. 27  Uniformity and requiring all clinical researchers to
abide by the same standards is imperative when implementing the
requirement of considering cultural factors in clinical research.
Because the FDA has authority to oversee clinical trials and
the NIH supports clinical trials, a federal law is needed.2 8  A
federal law would make it easier for the FDA to oversee clinical
trials and ensure researchers are complying with the law. It
would not make sense in this situation to give federal agencies
responsibility for implementing individual state regulations in
addition to any other federal laws to which the researchers might
222. See Duke Univ. Sch. of Law, Uniform Commercial Code, CORNELL U.L. SCH.
(July 2011), http://www.law.duke.edu/lib/researchguides/ucc.
223. See Cornell Univ. Law Sch. Legal Info. Inst., Uniform Laws, CORNELL U.L.
SCH., http://www.law.cornell.eduluniform/ (last visited Oct. 2, 2011) [hereinafter
Uniform Laws).
224. See Duke Univ. Sch. of Law, supra note 222.
225. Id.
226. See Food and Drug Administration Modernization Act of 1997, 21 U.S.C.
§ 379 (substantially recodifying the FDA's authority to govern clinical trials of
drugs and medical devices).
227. See Uniform Laws, supra note 223.
228. 21 U.S.C. § 379.
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be subject. This is an area that should continue to be entrusted
exclusively to the federal government and its agencies.
Finally, uniformity provided by a federal law can serve as an
example for researchers in other countries of how they can
properly consider cultural factors. Other countries recognize the
need to include minorities in clinical research and new legislation
has the potential to have an international impact.22
3. Additional Considerations
From a policy standpoint, researchers and the legislature
alike should include cultural aspects of minority populations as
criteria to be considered in clinical trials.o After years of
manipulation and abuse in clinical trials, wary minorities need to
feel their safety will be a concern if they participate in trials.231
Creating legislation that includes cultural differences is a way to
assuage the fears of distrustful minorities." When aiming to
increase minority participation in clinical trials through
legislation, Barbara A. Noah has explained the need to "proceed
with caution ... both because of the inherent risks of medical
research to individual participants and because some efforts at
racial inclusion may have unintended negative consequences.""
Though the NIH has recognized that cultural diversity is
important, more should and can be done to implement that
knowledge.234
Furthermore, researchers could be incentivized to consider
cultural variation among participants in their research. 23 5
229. See, e.g., Mahvash Hussein-Gambles et al., Why Ethnic Minorities are
Underrepresented in Clinical Trials: A Review of the Literature, 12 HEALTH & Soc.
CARE COMMUNITY 382, 382 (2004) (noting that exclusion of minorities "undermines
the UK government's National Health Service (NHS) plan for tackling inequalities,
and its core principle of providing culturally appropriate and accessible care for
different groups and individuals").
230. See WASHINGTON, supra note 65, at 386-88 (arguing that the
untrustworthiness of American medical research decreases the participation of
minorities and that laws have improved the situation, but that more needs to be
done). Including cultural factors is a way to make minorities feel more at ease and
trusting of clinical trials. See id. at 387.
231. See NIH GUIDELINES, supra note 154, at 12.
232. See id. (arguing that consultation between researchers and subjects can
increase appreciation of important cultural differences).
233. Noah, supra note 26, at 224.
234. NIH GUIDELINES, supra note 154, at 8 ("[Clonsiderable heterogeneity can
exist within health care settings and communities .... [C]ultural ... character-
istics can vary widely, along with major differences in health beliefs and practices.
Recruitment and retention strategies must therefore be based on the background
information about the particular groups of interest.").
235. Noah, supra note 26, at 232. Noah suggests incentivizing pharmaceutical
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Researchers, however, should not have to be incentivized to do
something that will positively help them and their participants.
The importance of cultural differences should not continue to be
ignored, especially when an effort is being made to include
minorities in clinical research. 3 6  A comprehensive clinical
research law will allow minorities to be included and given a voice.
Conclusion
The history of clinical research is tainted with manipulation
and the historical mistreatment of minorities in clinical
research. 3 7  The use of slaves for experiments, the Tuskegee
Study, and unethical experimentation on minority prisoners,
among other incidents, all contributed to minority fear of clinical
research.'" These fears still run deep."' Through the years, laws,
regulations, and guidelines have been promulgated to avoid
mistreatment of participants in clinical research.240
The development of informed consent has also played an
important role in protecting subjects in clinical research. 4' The
Nuremberg Code and the Declaration of Helsinki are just two
examples of the international community's recognition of the
importance of protecting human research subjects.24 2 In the
United States, the National Research Act was passed to protect
research subjects, leading to the creation of the Belmont Report.243
Guidelines have also been created to encourage minority inclusion
in clinical treatment, in an effort to ameliorate past injustices.24
The NIHRA was the beginning of a new line of thought, which
actively considered minority participation in clinical research as a
necessity.'24 This Act requires minorities to be included in clinical
companies "to make the effort to include diverse subject populations in trials of new
therapies" by having the FDA offer market exclusivity or having journals require
information on racial and ethnic subpopulations before being published. Id.
236. See NIH GUIDELINES, supra note 154, at 20.
237. See id. at 12; WASHINGTON, supra note 65, at 180; supra Part I.B.
238. Supra Part I.B.
239. See id.
240. See supra Part I.C.
241. Molly McGregor, Uninformed Consent: The United Nations' Failure To
Appropriately Police Clinical Trials in Developing Nations, 31 SUFFOLK
TRANSNAT'L L. REV. 103, 106-07 (2007).
242. See Office of Human Subjects Research, supra note 100; Office of Human
Subjects Research, supra note 107.
243. See PROT. OF HUMAN SUBJECTS, supra note 98.
244. See supra Part III.
245. National Institutes of Health Revitalization Act of 1993, 42 U.S.C. § 289a-2
(2006).
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research unless one of the exceptions is satisfied." The NIHRA is
a good beginning, but its exceptions too easily allow the exclusion
of minorities, as well as ignoring cultural factors.24
It is important to include not only minorities, but also
different cultures, in clinical research. Unfortunately, legislation
and guidelines currently in place do not cover the entire landscape
of clinical research.2" Cultural differences in approaches to
medicine are often overlooked, ignoring an important factor in
medicine. Cultural variety has a significant impact on approaches
to and views of medicine."
Passage of appropriate comprehensive legislation can address
the lack of consideration of cultural differences in clinical research
participants.2 5 0 Having this additional factor in the national
dialogue will also provide a way for clinical research in the United
States to evolve as the diversity of cultures and minority
populations in the United States continues to increase.
Congressional support will also help ensure fairness and proper
inclusion in clinical research studies.m
Cultural specificity in clinical research is beneficial to
researchers and subjects. By understanding and considering the
participants' viewpoints, researchers make participants feel more
comfortable, communicate with participants more easily, and
obtain more accurate results. 252 Until such legislation is passed,
cultural factors will continue to be overlooked, excluding some
cultures and culturally significant factors from clinical research.
246. Id.
247. See id.
248. See supra Part III.C.
249. See supra Part II.C.
250. See Ranganathan & Bhopal, supra note 41, at 334 (arguing that
governmental funding priorities in clinical research must be altered to include
minority groups' health concerns).
251. See, e.g., id. (stating that researchers have responded favorably to NIH
policies promoting the inclusion of minorities).
252. See supra Part IV.
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